Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
Condensed Statements of Cash Flows - USD ($) $ in Thousands	Sep. 30, 2025	Sep. 30, 2024
Operating activities:
Net loss	$ (51,924)	$ (27,082)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation, amortization, and impairment	418	571
Gain on contract termination	0	(300)
Share-based compensation	6,248	4,696
Amortization of debt issuance costs and discounts	8,246	8,015
Other, net	0	71
Changes in operating assets and liabilities:
Trade and other receivables, net	(4,413)	(1,228)
Inventories	(1,840)	(252)
Prepaid expenses and other assets	1,383	1,083
Accounts payable	276	146
Accrued expenses and other liabilities	(2,058)	(2,408)
Deferred revenue	(299)	(12,582)
Net cash used for operating activities	(43,963)	(29,270)
Investing activities:
Capital expenditures	(477)	(144)
Net cash used for investing activities	(477)	(144)
Financing activities:
Proceeds from shares issued under employee stock purchase plan	50	30
Proceeds from exercise of stock options, net	346	732
Proceeds from exercise of warrants, net	1,430	0
Repayment of debt principal including lease liabilities	(21)	(18)
Payments for royalty obligations	(11)	0
Payments for taxes on share-based compensation	(792)	(1,100)
Net cash provided by financing activities	101,957	83,435
Net increase in cash and cash equivalents	57,517	54,021
Cash and cash equivalents:
Cash and cash equivalents at beginning of period	71,546	23,872
Cash and cash equivalents at end of period	129,063	77,893
Supplemental disclosures of cash flow information:
Cash payments for interest	4,574	5,566
Cash payments for income taxes	0	305
Non-cash investing activities: capital expenditures in Accounts Payable	40	0
Costs associated with public equity offering-ATM in Accounts Payable	265	0
At-the-market offering
Financing activities:
Proceeds from common stock issued under public equity offering	21,227	11,817
Public Equity Offering
Financing activities:
Proceeds from common stock issued under public equity offering	$ 79,728	$ 71,974

Aquestive Therapeutics, Inc. 10-Q